Clinical Trial

Stop Retinal Ganglion Cell Dysfunction Study

Study Description

Stop Retinal Ganglion Cell Dysfunction Study

Glaucoma is a progressive disease resulting in blindness. Determining the onset of the disease, predicting its severity and the benefit of pressure lowering eye drops is key to clinical management aimed at maintaining useful vision with advancing age. This study will longitudinally monitor a population of glaucoma suspects (with positive factors for the disease but with normal vision) with noninvasive pattern electroretinogram (PERG) and other standard eye tests for glaucoma. The PERG measures the function of retinal ganglion cells (RGCs) that are the parent neurons of the optic nerve. RGCs may become dysfunctional before dying and their function restored with pressure-lowering eye drops. Glaucoma suspects with abnormal PERG will be randomized to treatment with eye drops, while those with normal PERG will be left untreated. All patients will be monitored with PERG, Optic Coherence Tomography (OCT) and other ancillary tests every 6 months over 4 years.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Drug - Latanoprost

Lower intraocular pressure (IOP) by increasing outflow of fluid from the eye.

Drug - Bimatoprost

Lower intraocular pressure by increasing outflow of fluid from the eye.

Drug - Travoprost

Lower intraocular pressure by increasing outflow of fluid from the eye.

Drug - Timolol

Lower intraocular pressure by decreasing production of fluid

Drug - Dorzolamide

Lowers intraocular pressure by decreasing intraocular fluid production

Drug - Brinzolamide

Lowers intraocular pressure by decreasing intraocular fluid production

Drug - Acetazolamide

Lowers intraocular pressure by decreasing intraocular fluid production

Drug - Methazolamide

Lowers intraocular pressure by decreasing intraocular fluid production

Additional Information

Official Study Title

Stop Retinal Ganglion Cell Dysfunction Study

Clinical Trial ID

NCT02390284

ParticipAid ID

penGYa